Harrison Kitty
Neurology Nursing Specialist, Department of Neurology, Tergooiziekenhuizen, Blaricum, Netherlands.
Br J Nurs. 2014;23(11):582-9. doi: 10.12968/bjon.2014.23.11.582.
The availability of treatments for multiple sclerosis (MS) has increased substantially over the past decade. Once-daily fingolimod 0.5 mg capsules (Gilenya, Novartis Pharma) were approved in the European Union in March 2011 as the first oral disease-modifying therapy for patients with relapsing MS. This review summarises the efficacy and safety of fingolimod, and discusses practical considerations for MS specialist nurses. Fingolimod has demonstrated efficacy in the treatment of relapsing-remitting MS, as assessed by relapse measures, inflammatory disease activity and brain volume loss. Evaluation of its safety profile suggests a need for monitoring procedures for specific adverse events, including transient, mostly asymptomatic, reductions in heart rate, blood pressure increases, macular oedema and liver enzyme elevations. The MS nurse is likely to be involved in monitoring treatment initiation, providing support in the case of adverse events and promoting patient adherence to the prescribed treatment regimen.
在过去十年中，多发性硬化症（MS）的治疗方法有了显著增加。每日一次服用0.5毫克的芬戈莫德胶囊（捷灵亚，诺华制药）于2011年3月在欧盟获批，成为复发型MS患者的首个口服疾病修正疗法。本综述总结了芬戈莫德的疗效和安全性，并讨论了MS专科护士的实际注意事项。通过复发指标、炎症性疾病活动和脑容量损失评估，芬戈莫德已证明对复发缓解型MS有效。对其安全性的评估表明，需要针对特定不良事件进行监测，包括短暂的、大多无症状的心率降低、血压升高、黄斑水肿和肝酶升高。MS护士可能会参与监测治疗开始情况，在出现不良事件时提供支持，并促进患者遵守规定的治疗方案。
